

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

CURRENT PRACTICE

*Medical Director & Chief Surgeon, [LasikPlus-Austin](#)
Warfighter Refractive Eye Surgery Consultation Service, [Darnall Army Medical Center](#)*

*9705 Research Blvd.
Austin, Texas 78759
(866) 755-2026*

Investigator, [Retina Research Center](#)

*Austin Medical Plaza
3705 Medical Parkway, Suite 420
Austin, Texas 78705
(512) 454-0138*

Medical Director & Chief Surgeon, [LasikPlus Houston](#)

*3700 Buffalo Speedway Suite 325
Houston, Texas 77098
(866) 755-2026*

EDUCATION

UNIVERSITY OF TEXAS Austin, Texas
Bachelor of Arts, Dean's Honor Roll, Graduated May 1987
BAYLOR COLLEGE OF MEDICINE Houston, Texas
Doctor of Medicine, Top ¼, Graduated May 1991

NAVY

OFFICER INDOCTRINATION SCHOOL Newport, Rhode Island
Graduated 2nd in class, With Academic and Military Distinction, February 1988
NAVAL MEDICAL CENTER San Diego, California
Transitional Internship, Graduated 2nd in class, June 1992
NAVAL TRAINING CENTER San Diego, California
Program Director, Corpsman Combat Medical Training Program
Junior Medical Officer, Detached December 1992
NAVAL AEROSPACE MEDICAL INSTITUTE Pensacola, Florida
Aerospace Medicine, Aviation Physiology, and Helicopter Flight Training
Graduated 3rd in class, With Honors, June 1993
TRAINING AIR WING FOUR Corpus Christi, Texas
Chief Flight Surgeon, Naval Air Training Command
Blue Angels Regional Aeromedical Coordinator
Medical Director, Search and Rescue Units, US Coast Guard and Navy
Lieutenant Commander, Separated June 1996

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

RESEARCH FELLOWSHIP

CENTER FOR RESEARCH ON OCULAR THERAPEUTICS AND BIODEVICES Charleston, South Carolina
David J. Apple, M.D., Director; Kerry D. Solomon, M.D., Co-Director
Refractive Surgery and Cataract Implant Technology
FDA and Sponsored Clinical Trials
Director, Miyake-Apple Lab Research Center, Completed June 1997

RESIDENCY

STORM EYE INSTITUTE Charleston, South Carolina
Chief Resident, Completed June 2000

CLINICAL PRACTICE

TEXAN EYE CARE Georgetown, Texas, June 2000 to May 2002
Comprehensive Ophthalmology, Cataract Surgery, LASIK
EYE CENTER OF CENTRAL TEXAS Temple, Texas, June 2002 to November 2005
Medical Director, Cataract Surgery, Premium IOLs, LASIK, Comprehensive Ophthalmology
Medical Director, Central Texas Day Surgery Center
LASIKPLUS Austin, Texas, November 2005 - *current*; Houston, Texas, December 2012 - *current*
Medical Director & Chief Surgeon, Refractive Laser Eye Surgery
DARNALL ARMY MEDICAL CENTER Fort Hood, Texas, February 2009 - *current*
Warfighter Refractive Eye Surgery Program, Consultation Service
LASIK/PRK, Cataract Surgery, Premium IOLs, Phakic IOLs, Comprehensive Ophthalmology

CLINICAL RESEARCH

CENTER FOR RESEARCH ON OCULAR THERAPEUTICS AND BIODEVICES Charleston, South Carolina
KEYSTONE CLINICAL RESEARCH Austin, Texas
RETINA RESEARCH CENTER Austin, Texas, June 2009 – *current*
Principal Investigator, Anterior Segment FDA Clinical Trials

POSITIONS HELD (Current and Previous)

Visiting Lecturer, The University of Texas at Austin
Adjunct Faculty, US Army Medical Department
Treasurer, Texas Ophthalmological Association
Budget and Finance Committee, Chair, Texas Ophthalmological Association
Rick Management Committee, LCA Vision
Executive Council Member, Texas Ophthalmological Association
Maintenance of Certification Education Committee, American Academy of Ophthalmology
Comprehensive Ophthalmology Task Force, American Academy of Ophthalmology
Knowledge Base Panel, Comprehensive Ophthalmology, American Academy of Ophthalmology
Secretary, Texas Ophthalmological Association
Membership Committee, Chair, Texas Ophthalmological Association
Young Ophthalmology Chair, Texas Ophthalmological Association
Editorial Committee, The Profession of Ophthalmology, American Academy of Ophthalmology
Young Ophthalmologist Committee, American Academy of Ophthalmology

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

RECOGNITIONS

Qualified and Listed at [Trusted LASIK Surgeons](#), an online directory of LASIK, cataract and vision correction experts that screens all surgeons featured in its directory based upon professional accomplishments, experience, and patient care standards.

Leadership Achievement Award, American Academy of Ophthalmology

Featured Speaker, 3rd Annual Central Texas Sports Medicine Workshop, Southwestern University, Georgetown, Texas.

Keynote Lecturer, XVth Congress of the European Society of Cataract and Refractive Surgeons, Prague, Czech Republic

ASCRS Film Festival “Grand Prize” (co-producer with Robert H. Osher, M.D.), American Society of Cataract and Refractive Surgery, Annual Symposium, Boston, Massachusetts

Best Paper in Session award, American Society of Cataract and Refractive Surgery, Annual Symposium, Boston, Massachusetts

Navy and Marine Corps Commendation Medal

Navy Achievement Medal

Navy Flight Surgeon of the Year nominee

Graduated With Honors, Naval Aerospace Medical Institute

Outstanding of the Outstanding Intern Award, Naval Medical Center, San Diego

Academic and Military Distinction, Naval Officer Indoctrination School

Cum Laude Ampla et Magna, The University of Texas

Golden Key National Honor Society, The University of Texas

PROFESSIONAL SOCIETIES

American Academy of Ophthalmology

International Society of Refractive Surgery

American Society of Cataract and Refractive Surgery

Austin Ophthalmological Society

Texas Medical Association American

Texas Ophthalmological Association

Travis County Medical Society

LICENSURE Texas State Board of Medical Examiners

BOARD CERTIFICATION American Board of Ophthalmology

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

PUBLICATIONS

1. Koch DD, Smith SH, Whiteside SB. Limbal and scleral wound healing. In: Beuerman RW, Crosson CE, Kaufman HE, editors. Healing Processes in the Cornea. Advances in Applied Biotechnology Series. Houston: Gulf Publishing, 1989; v. 1, chap. 13.
2. Kent DG, Solomon KD, Peng Q, Whiteside SB, Brown SJ, Apple DJ. Effect of surface photorefractive keratectomy and laser in situ keratomileusis on the corneal endothelium. *J Cataract Refract Surg* 1997;23:386-397.
3. Osher RH, Whiteside SB, Solomon KD. Video: The Mature Cataract & Its Sharp Edges: Fact or Fiction. Producer: Robert H. Osher, M.D. In: 1997 ASCRS Film Festival Winners Video. Denver: National Audio Video, Inc, 1997.
4. Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ. Topical ketorolac 0.5% versus flurbiprofen 0.03% for inhibition of miosis during cataract surgery. *Arch Ophthalmol* 1997; 115:1119-122.
5. Kent DG, Peng Q, Isaacs RT, Whiteside SB, Apple DJ. Security of capsular fixation of silicone plate IOLs. A comparison of small hole versus large hole plate IOLs. *J Cataract Refract Surg* 1997;23:1371-1375.
6. Whiteside SB, Apple DJ, Peng Q, Isaacs RT, Guindi A, Draughn RA. Fixation elements on plate IOLs. Large positioning holes to improve security of capsular fixation. *Ophthalmology* 1998;105:837-842.
7. Whiteside SB, Guindi A, Peng Q, Visessook N, Apple DJ. Cataract surgery and IOL implantation: how are we doing? *Invest Ophthalmol Vis Sci* 1998;39(4):S53. Association for Research in Vision and Ophthalmology abstract 235.
8. Kent DK, Peng Q, Isaacs RT, Whiteside SB, Barker DL, Apple DJ. Mini-haptics to improve capsular fixation of plate-haptic silicone intraocular lenses. *J Cataract Refract Surg* 1998;24:666-671.
9. Whiteside SB. Improving cortical clean-up can help to prevent PCO. *Ophthalmology Times* 1998;23:1,52-53.
10. Apple DJ, Peng Q, Visessook N, Werner L, Pandey SK, Escobar-Gomez M, Ram J, Whiteside SB, Schoderbeck R, Ready EL, Guindi A. Surgical prevention of posterior capsule opacification. Part 1: Progress in eliminating this complication of cataract surgery. *J Cataract Refract Surg* 2000;26:180-187.
11. Whiteside SB, Holzer MP, Vroman D, Kaufer P, Solomon KD. Diffuse lamellar keratitis: Experimental animal model using the rabbit eye. Manuscript in preparation. (Presented by co-author at American Society of Cataract and Refractive Surgery, Annual Symposium, April 2001, San Diego. Awarded Best Paper in Session.)

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

13. Allergan Research Group, et al. A multicenter, double-masked, randomized, parallel study of the safety and efficacy of 0.2% Brimonidine tartrate/0.5% Timolol combination ophthalmic solution twice-daily compared with 0.5% Timolol twice-daily or Alphagan® three-times-daily for three months (plus 9-month, masked extension) in patients with glaucoma or ocular hypertension. Manuscript prepared.
14. ORA, Inc. Research Group, et al. A three-month comparison of the safety, efficacy, and clinical success of Brimonidine with Latanoprost vs Latanoprost with Timolol. Manuscript prepared.
15. Allergan Research Group, et al. A 14 day multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of the safety, efficacy and tolerability of AGN 195795 0.1%, 0.3% and 1% ophthalmic suspension dosed once- or twice-daily in patients with ocular hypertension or chronic glaucoma. Manuscript prepared.
16. Merck Research Group, et al. A parallel, randomized, observer-masked, multicenter study comparing the ocular hypotensive effect of 2% Dorzolamide hydrochloride/0.5% Timolol maleate ophthalmic solution to the concomitant administration of 2% Brimonidine tartrate ophthalmic solution and 0.5% Timolol maleate ophthalmic solution in patients with elevated intraocular pressure. Manuscript prepared.
17. Santen Research Group, et al. A randomized, double-masked, parallel-group, multi-center dose-response trial of AFP-168 ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Manuscript prepared.
18. Santen Research Group, et al. A randomized, double-masked, parallel-group, multicenter, 12-month trial comparing the efficacy and safety of tafluprost 0.0015% with timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension. Manuscript prepared.
19. Takeda, Theradex. A double-blind, randomized, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin subjects with primary dyslipidemia. Manuscript prepared.
20. Pfizer Global Research and Development. A Phase I/II Prospective, Randomized, Double Masked, Vehicle and Comparator Controlled, Dose Ranging Study of CP-690,550 in Subjects with Dry Eye Disease. Manuscript in preparation.

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

PRESENTATIONS

1. Comparative cytokine expression following PRK and LASIK corneal refractive surgery using RT-PCR. American Society of Cataract and Refractive Surgery, Annual Symposium, April 1997, Boston, Massachusetts. Awarded Best Paper in Session.
2. Video: The Mature Cataract & Its Sharp Edges: Fact or Fiction. Osher RH, Whiteside SB, Solomon KD. American Society of Cataract and Refractive Surgery, Annual Symposium, Film Festival, April 1997, Boston, Massachusetts. Awarded "Grand Prize".
3. Fixation elements on plate IOLs. Large positioning holes to improve fixation. Storm Eye Institute, Comprehensive Update Meeting, May 1997, Charleston, South Carolina.
4. Non-AIDS related conjunctival Kaposi's sarcoma. Combined Theobald and Hogan Societies, Ophthalmic Pathology Meeting, May 1997, Coronado, California.
5. Update on Pathology of Refractive Surgery. Kentucky Academy of Eye Physicians and Surgeons, Spring Meeting, June 1997, Wild Dunes, South Carolina.
6. New findings in plate IOLs. Kentucky Academy of Eye Physicians and Surgeons, Spring Meeting, June 1997, Wild Dunes, South Carolina.
7. Keynote Lecture: Wound healing response following LASIK and PRK. XVth Congress of the European Society of Cataract and Refractive Surgeons, September 1997, Prague, Czech Republic.
8. Cataract surgery and IOL fixation: how are we doing? American Society of Cataract and Refractive Surgery, Annual Symposium, April 1998, San Diego, California.
9. Poster: Pathologic analysis of surgical quality: a look at haptic fixation and cortical clean-up. Association for Research in Vision and Ophthalmology, Annual Meeting, May 1998, Fort Lauderdale, Florida.
10. Cortical clean-up and IOL implantation: a pathologic review of modern cataract surgery over the past 20 years. Storm Eye Institute, Comprehensive Update Meeting, June 1998, Charleston, South Carolina.
11. Pseudo-pseudotumor cerebri masquerading as post-lumbar puncture headache. Storm Eye Institute, Comprehensive Update Meeting, June 1999, Charleston, South Carolina.
12. Phacoemulsification: A surgeon's perspective. American Society of Ophthalmic Registered Nurses, Phacoemulsification Essentials for Nurses and Technicians, June 1999, Charleston, South Carolina.
13. Diffuse lamellar keratitis following LASIK. A prospective animal study designed to determine etiology and therapeutic options. Storm Eye Institute, Comprehensive Update Meeting, June 2000, Charleston, South Carolina.
14. Young Ophthalmologist Noontime Symposium, moderator. American Academy of Ophthalmology, Annual Meeting, Young Ophthalmologist Noontime Symposium, October 1999, Orlando, Florida.

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

15. Evaluating a Practice Opportunity. American Academy of Ophthalmology, Annual Meeting, Young Ophthalmologist Noontime Symposium, October 2000, Dallas, Texas.
16. Coding Basics for Young Ophthalmologists, moderator. American Academy of Ophthalmology, Annual Meeting, Young Ophthalmologist Half-Day Program, November 2001, New Orleans, Louisiana.
17. Eye Trauma and Field Evaluation. Southwestern University, "Medical Aspects", April 2002, Georgetown, Texas.
18. Evaluating a Practice Opportunity. American Academy of Ophthalmology, Annual Meeting, Young Ophthalmologist Half-Day Program, October 2002, Orlando, Florida.
19. Eye Trauma and Field Evaluation. Southwestern University, "Medical Aspects", November 2002, Georgetown, Texas.
20. Field Evaluation of Eye Injuries. Central Texas Athletic Trainer's Workshop, Southwestern University, November 2002, Georgetown, Texas.
21. Young Ophthalmologist Half-Day Program, moderator. American Academy of Ophthalmology, Annual Meeting, Young Ophthalmologist Half-Day Program, October 2003, Anaheim, California.
22. The Essentials of the Eye Exam. 2nd Annual Greater Central Texas Area Athletic Trainers' Workshop, Southwestern University, November 2003, Georgetown, Texas.
23. Marketing Your Practice. American Academy of Ophthalmology, Annual Meeting, Young Ophthalmologist Half-Day Program, October 2004, New Orleans, Louisiana.
24. The Eye Examination, lecture and lab. Featured Speaker. 3rd Annual Central Texas Sports Medicine Workshop, Southwestern University, November 2004, Georgetown, Texas.
25. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, January 2005, Austin, Texas.
26. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Mary Hardin-Baylor, Athletic Training Curriculum, March 2005, Belton, Texas.
27. LASIK, Botox, and Ocular Nutrition. A Day Just for Women, Mayborn Convention Center, April 2005, Temple, Texas.
28. For Your Eyes Only: Macular Degeneration, Cataracts, and Ocular Nutrition. King's Daughters Hospital, "Brown Bag Lunch Lecture" Series, June 2005, Temple, Texas.
29. Sports-Related Eye Injuries. Southwest Athletic Trainers' Association, 51st Annual Meeting and Clinical Symposium, July 2005, Houston, Texas.

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

30. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, January 2006, Austin, Texas.
31. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Mary Hardin-Baylor, Athletic Training Curriculum, March 2006, Belton, Texas.
32. The Eye Exam, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, April 2007, Austin, Texas.
33. Core Content for Maintenance of Certification. American Academy of Ophthalmology, Annual Meeting, Noontime Session, Making Sense of Maintenance of Certification, November 2007, New Orleans, Louisiana.
34. The Eye Exam, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, February 2008, Austin, Texas.
35. The Eye Exam, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2009, Austin, Texas.
36. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2010, Austin, Texas.
37. The Eye Exam, lecture and lab. University of Texas at Austin, High School Sunday, Professional Athletic Training Educational Seminar, April 2010, Austin, Texas.
38. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2011, Austin, Texas.
39. The Eye Exam, lecture. University of Texas at Austin, Athletic Training Curriculum, March 2012, Austin, Texas.
40. Direct Ophthalmoscopy, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2012, Austin, Texas.
41. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2012, Austin, Texas.
42. The Eye Exam, lecture. University of Texas at Austin, Athletic Training Curriculum, March 2013, Austin, Texas.
43. Direct Ophthalmoscopy, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2013, Austin, Texas.
44. Field Assessment of Sports-Related Ocular Trauma, lecture and lab. University of Texas at Austin, Athletic Training Curriculum, March 2013, Austin, Texas.

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

FDA CLINICAL STUDIES

1. A multicenter, double-masked, randomized, parallel study of the safety and efficacy of 0.2% Brimonidine tartrate/0.5% Timolol combination ophthalmic solution twice-daily compared with 0.5% Timolol twice-daily or Alphagan® three-times-daily for three months (plus 9-month, masked extension) in patients with glaucoma or ocular hypertension. Allergan.
2. A three-month comparison of the safety, efficacy, and clinical success of Brimonidine with Latanoprost vs Latanoprost with Timolol. ORA.
3. A 14 day multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of the safety, efficacy and tolerability of AGN 195795 0.1%, 0.3% and 1% ophthalmic suspension dosed once- or twice-daily in patients with ocular hypertension or chronic glaucoma. Allergan.
4. A parallel, randomized, observer-masked, multicenter study comparing the ocular hypotensive effect of 2% Dorzolamide hydrochloride/0.5% Timolol maleate ophthalmic solution to the concomitant administration of 2% Brimonidine tartrate ophthalmic solution and 0.5% Timolol maleate ophthalmic solution in patients with elevated intraocular pressure. Merck.
5. A randomized, double-masked, parallel-group, multi-center dose-response trial of AFP-168 ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Santen.
6. A randomized, double-masked, parallel-group, multicenter, 12-month trial comparing the efficacy and safety of tafluprost 0.0015% with timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension. Santen.
7. A double-blind, randomized, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin subjects with primary dyslipidemia. Takeda, Theradex.
8. A Phase I/II Prospective, Randomized, Double Masked, Vehicle and Comparator Controlled, Dose Ranging Study of CP-690,550 in Subjects with Dry Eye Disease. Pfizer.
9. A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis. Alcon.
10. A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis. LUX BioSciences.
11. A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis. Abbott (M10-880).
12. A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis. Abbott (M10-877).

CURRICULUM VITAE
STEPHEN B. WHITESIDE, M.D.

13. A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis. Abbott (M11-327).
 14. A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating the Safety, Tolerability, Immunogenicity Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G in Subjects With
 15. Advanced Dry, Age-Related Macular Degeneration (ARMD) Including Geographic Atrophy. Pfizer.
 16. A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment. XOMA.
 17. A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-uveitis. XOMA.
- ** Other non-FDA, corporate-based laboratory and clinical studies